Celcuity, Inc., a cellular analysis company based in Minneapolis, went public in 2017 and employs 45 people. Its main product, gedatolisib, targets specific cancer pathways and is in trials for treating advanced breast cancer.
Based on our analysis, Celcuity Inc. has been assigned an overvalued rating of 1 out of 5 stars due to several concerning financial metrics when compared to its sector.
The company's Return on Equity (ROE) ratio stands at -45.63, which indicates that the company is generating negative returns for its shareholders. A negative ROE suggests inefficiency in utilizing equity capital, which is concerning for potential investors. In comparison, the sector average is -74.39, highlighting that while Celcuity’s performance is better than the sector, it still reflects significant underlying issues.
Furthermore, Celcuity’s Return on Assets (ROA) ratio is -33.35. This ratio measures how effectively a company uses its assets to generate profit. A negative ROA signals that the company is not able to convert its assets into earnings efficiently. The sector's average ROA is -47.95, indicating that while Celcuity performs better than its peers, it still faces operational challenges that could hinder future profitability.
Lastly, the net profit margin for Celcuity is not available, while the sector experiences a margin of -142.86. A negative net profit margin indicates that a company is incurring losses relative to its revenue, suggesting operational inefficiencies or high costs.
In summary, despite some relative strengths in comparison to its sector, Celcuity Inc. exhibits troubling financial metrics that contribute to its low valuation rating.
This is not a comprehensive overview of our valuation and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!